250 results about "Disease specific" patented technology

A system and process for providing a computerized medical and biographical records database and diagnostic information. A medical records database and diagnostic program is stored on a central computer that is accessible to individuals using remotely situated computers connected to a computer network. Individual patient medical and biographical records are owned by individual patients who can enter information in their record as well as grant or deny authorization to others, such as health care professionals, insurance providers and other entities, to review part or all of their record. The diagnostic program provides a series of diagnostic questions to an individual who must respond either "yes" or "no" to each question. Each potential response is weighted relative to its importance to a particular disease diagnosis. Relative weights for all responses to diagnostic questions are summed to identify potential diagnoses to connected to the answered questions. The diagnostic program provides the individual with a list of potential diagnoses as well as permitting the individual to save the information to his or her individual medical and biographical record. The information maintained in the above system and process is utilized for health care financing and insurance.

An integrated passive wireless chip diagnostic sensor system is described that can be interrogated remotely with a wireless device such as a modified cell phone incorporating multi-protocol RFID reader capabilities (such as the emerging Gen-2 standard) or Bluetooth, providing universal easy to use, low cost and immediate quantitative analyses, geolocation and sensor networking capabilities to users of the technology. The present invention can be integrated into various diagnostic platforms and is applicable for use with low power sensors such as thin films, MEMS, electrochemical, thermal, resistive, nano or microfluidic sensor technologies. Applications of the present invention include on-the-spot medical and self-diagnostics on smart skin patches, Point of Care (POC) analyses, food diagnostics, pathogen detection, disease-specific wireless biomarker detection, remote structural stresses detection and sensor networks for industrial or Homeland Security using low cost wireless devices such as modified cell phones.

A method and apparatus are provided for identifying a biological sample obtained during either paternity screening, genetic screening, prenatal diagnosis, presymptomatic diagnosis, diagnosis to detect the presence of a target microorganism carrier detection analysis, forensic chemical analysis, or diagnosis of a subject to determine whether a subject is afflicted with a particular disease or disorder, or is at risk of developing a particular disorder, wherein the result obtained from the analysis is associated with the unique DNA fingerprint biological barcode of the genotype of the subject being analyzed. The methods and apparatus of the invention have application in the fields of diagnostic medicine, disease diagnosis in animals and plants, identification of genetically inherited diseases in humans, family relationship analysis, forensic analysis, and microbial typing.

We present a data-driven system that seamlessly integrates the compilation of a diverse set of patient electronic medical records, family history, and environmental risk factor databases, a program that determines correlations and assigns weights through a neural network between illness and the state of symptoms, a program to create disease-specific questionnaires and content, a program alert that informs users of trends and potential illness outbreaks due to anomalous changes in regional or national symptom trends, and a program that enables medical practitioners to view patient-generated records and manage an online referral system. The automated diagnoses and alerts allow users to make informed and rapid medical treatment decisions.

The invention provides compositions and methods for signal activated RNA interference (saRNAi), preferably in vivo. The invention provides polynucleotides that switches between an inactive form and an active form upon covalent or non-covalent interaction with one or more specific chemical signals, such as disease-specific mRNA, miRNA, or other cellular RNA products with sequences that characterize diseased states of the cell. The interaction between the subject polynucleotides and the signals is preferably mediated by hybridization, which exposes, facilitates the formation, and/or allows the formation of a substrate that can be processed by proteins of the RNAi pathway (such as Dicer). The input and output of multiple different polynucleotides of the invention can form an in vivo signaling network. In addition, the multiple input signals can be integrated to modulate the activity of the subject polynucleotides.

The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1. In addition, the invention includes methods of diagnosing Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis in a subject. Also, the invention provides methods of identifying substances for the treatment or prevention of Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis and kits using the binding proteins of the invention.

A system and method for determining individualized medical intervention for a particular disease state, and especially for cancers, that includes the molecular profiling of a biological sample from the patient, determining whether any molecular findings including one or more genes, one or more gene expressed proteins, one or more molecular mechanisms, and/or combinations of such exhibit a change in expression compared to a reference, and identifying a non-specific disease therapy or agent capable of interacting with the genes, gene expressed proteins, molecular mechanisms, or combinations of such molecular findings that exhibited a change in expression.

Illness signatures are mathematically characterized by entrainment relationships among multiple time series representations of physiological processes. Such characteristics include time and phase lags, window lengths for optimum detection, which time series are most entrained with each other, the degree of entrainment relative to the rest of the large database, and the concordance or discordance of the time-varying changes. These optimum disease-specific characteristics can be determined, for example, from large, clinically well-annotated databases of time series representations of physiological processes during health and illness. These characteristics of the entrainment relationships among multiple time series representations of physiological processes are used to make mathematical and statistical predictive models using multivariable techniques such as, but not limited to, logistic regression, nearest-neighbor techniques, neural and Bayesian networks, principal and other component analysis, and others. These models are quantitative expressions that transform measured characteristics to the probability of an illness, or p(illness).

A method and system use a combined contribution of multiple disease risk factors to predict the risk of onset of particular diseases in an individual. The prediction models use information from separate studies. Multiple disease predictions for a predetermined number of diseases are made. The predictions are used to calculate the individual's mortality risk and life expectancy. The life expectancy is compared to that of age and gender matched peers to determine the inner age of the individual.

An evidence based cost modeling and predictive analysis system, and an incentives based plan to reduce healthcare costs are disclosed. An analytics system may generate incremental expenditures among overweight and obese individuals, predictive forecasts of future medical costs, and predictive forecast of cost reduction based on financial incentives to recipients. The forecasts may include statistical trends, prevalence of diseases based on body mass index, and medical evidence associated with specific illnesses. A computer based program may process and analyze dependent and independent variables in electronically stored information (for example insurance, health and medical records). A health insurance provider may provide an annual rebate on paid premiums to recipients based on a qualifying annual BMI as an incentive. The recipients may receive the rebates in a qualified health reimbursement account (HRA) managed by the recipients towards future healthcare related expenditures.

This invention is directed to a method for preparation of a biological sample for measurement of protein epitopes that allows for the preservation of intracellular protein epitopes and detection of signal transduction pathways based on the ability to capture transient activation states of the epitopes. The method provided by the invention allows for the rapid fixation of biological samples containing red blood cells, to ensure that epitopes of signal transduction molecules and other intracellular protein epitopes are preserved in the active state. The method of the invention further allows for lysis of red blood cells, thereby making it a useful method for cytometric analysis of biological samples, including, for example, whole blood, bone marrow aspirates, peritoneal fluids, and other red blood cell containing samples. The invention also provides a method to recover or “unmask” epitopes on intracellular antigens that have been made inaccessible by the cross linking fixative necessary to fix the sample. Significantly, the methods of the invention allow preservation and analysis of phospho-epitope levels in biological samples taken directly from patients to determine disease-specific characteristics.

Chemical compositions of bioactive compounds and/or bioactive molecules for lowering the risks of Alzheimer's, Cardiovascular and Diabetes diseases are described. Targeted, passive and programmable/active deliveries of the bioactive compounds and/or bioactive molecules are described. Subsystems for detection of disease specific biomarkers/an array of disease specific biomarkers and programmable/active delivery of the bioactive compounds and/or bioactive molecules in near real-time/real-time are also described.

A disease-specific ontology crafted by a consensus of expert clinicians may be used to semantically characterize/provide semantic meaning to dynamically changing patient electronic medical record (EMR) data in critical care settings. Hierarchical, directed node-edge-node graphs (concept maps or Vmaps) developed with an end-user friendly graphical user interface and ontology editor, can be used to represent structured clinical reasoning and serve as the first step in disease-specific ontology building. Disease domain Vmaps reflecting expert clinical reasoning associated with management of acute illnesses encountered in critical care settings (e.g. ICUs) that extend core clinical ontologies, developed and reviewed by experts, are in turn extended with existing medical ontologies and automatically translated to a domain ontology processing engine. Semantically-enhanced EMR data derived from the ontology processing engine is incorporated into both real-time ‘track and trigger” rule engines and machine learning training algorithms using aggregated data. The resulting rule engines and machine-learnt models provide enhanced diagnostic and prognostic information respectively, to assist in clinical dual modes of reasoning (analytical rules and models based on experiential data) to assist in decisions associated with the specific disease in acute critical care settings.

A handheld device used to assist a user in performing daily activities and in being socially active. The device can also be used to assist in monitoring dietary, medication, and supplement intakes, pain and stress levels, vitals, exercise, sleep quality, and other aspects of better living. The device can be personalized to monitor specific diseases or chronic conditions, and can provide access to specific environmental data that can be used to support better living.

A disease risk evaluation and education tool, preferably implemented in logic on a computing device such as a Personal Digital Assistant, permits a user to input patient-specific data relevant to evaluating that patient's risk for a particular disease, e.g., coronary heart disease. The tool's logic calculates the equivalent age of the patient, based on the Framingham data set and on the input data, and presents one or more treatment recommendations.

An echocardiogram report generation method and system are disclosed for creating a complete medical report describing an echocardiogram without dictation, transcription or typing. The report is tailored to describe an individual patient and generated in complete grammatically complex sentences in response to the user's input with a text report that is complete and understandable for a primary care physician. The method and system provides the user the parallel options of an anatomical structure approach and a disease-specific approach in order to amplify the description of the echocardiogram in specific areas and give a more meaningful report. The echo report generated by the method and system creates a table of measurements and calculations in compact form, omitting any data fields not used. The method and system guides the user through the various areas of the heart which merit comment on the report and provides clear color coded segments of the heart muscle and provides several heart segment classifications so that the user can use his favored classification scheme. Diagnostic possibilities are provided for inclusion in the report conclusions.

The invention provides therapeutic or diagnostic antibodies with modified N— or C-terminal sequences that are enriched with lysine or tyrosine residues. These lysine or tyfosine residues can be used to couple radioisotopes, cytotoxic agents, or detectable labels. The increased stoichiometric ratios of these agents in the antibody conjugates lead to improved therapeutic efficacy or enhanced detection sensitivity. Non-limiting examples of antibodies suitable for the present invention include anti-CD22, anti-ErbB2, anti-VEGF, anti-EGFR, anti-VEGFR, anti-Her-3, anti-Her-4, anti-CEA, anti-CTLA-4, anti-CD4, anti-CD3, anti-CD20, anti-TNF-a, anti-CD11a, anti-Lewis Y antigen, anti-TrailR, anti-IL2R, anti-CD30, anti-CD146, anti-CD147, anti-alpha V integrin beta, anti-CD19, anti-GD2, anti-3H11, anti-EBV, anti-HIV, anti-HBV, anti-HCV, and other disease-specific antibodies.

The present invention relates to an itemized analytical tool which creates a series of standardized and objective metrics related to each individual step in the overall process of pharmaceutical development and delivery. The individual steps can be divided into two main sections: pre and post regulatory approval. Pre-approval data analysis relates to the various steps involved in clinical trials, while post-approval analysis relates the multiple steps related to everyday use. The data analytics take into account the various contributions individual stakeholders and institutions play in determining overall safety and effectiveness of medical agents. The agent-specific data can in turn be cross referenced with individual patient and disease specific data, in order to provide customizable decision support.